TUSTIN, Calif. (Map) - TUSTIN, Calif., Jan. 6 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), a vertically integrated pharmaceutical company with operations in China and the US, announced today industry analyst Lauren Rudd has issued a strong buy recommendation for AMDL in his year-end financial research report on the Company.

The report projects a 12-month target price of $5.00 for AMDL and highlights the Company's:

-- Consistent, positive historical financial performance over the past four years -- Most recent operational changes and business updates, including an updated overview of AMDL's China-based subsidiary Jade Pharmaceuticals, Inc. -- FY2009 product pipeline -- FY2009 plans for the AMDL ELISA DR-70(R) (FDP) cancer monitoring test; best-selling Human Placenta Extract (HPE) anti-aging product line; and MYHPV Chip(R) diagnostic test kit which detects approximately 28 different strains of the Human Papilloma Virus.

The research report also provides a thorough peer group comparison with valuation analyses, views and opinions on AMDL's projected financial performance for the 2009 fiscal year, and historical financials.

According to Mr. Rudd, "AMDL has taken major initiatives to build its strengths while reorganizing top management and still producing respectable financials which has resulted in AMDL being one of the most under priced stocks we have seen in a long time."

A full copy of the report is available for downloading online at http://www.ruddreport.com or by contacting Ms. Kristine Szarkowitz, AMDL's Director Investor Relations, at kszarkowitz@amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to AMDL Inc., except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

AMDL Contact: Kristine Szarkowitz Director-Investor Relations kszarkowitz@amdl.com (Tel :) 206.310.5323